The $45 million BioMedTech Horizons (BMTH) programme is inviting expressions of interest (EOIs) from medtech innovators for funds of up to $1 million over a two-year period. The fund will support small to medium-size enterprises (SMEs) in the development and commercialisation of new cutting-edge medical technologies.
This is the third round of the programme and targets innovative solutions to address unmet clinical needs in three key focus areas:
- Digitally enabled medical devices in mobile health, health information technology, wearable devices, telehealth and telemedicine, and digitally-enabled personalised medicine;
- Digitally enabled implantable medical devices addressing unmet needs in any therapeutic area; and
- General medical devices in the areas of regenerative medicine, women’s health, cardiovascular, orthopaedics, neuroscience, general surgery and oncology.
The allocation of grants is overseen by a committee managed by MTPConnect and includes AusBiotech, the MTAA and the Department of Health.
The programme is intended to address gaps in early biomedical and medical technology product development and to increase the number of viable new health technologies for commercialisation. Grant opportunities will cover the entire research pipeline from basic to applied research, with a focus on the translation and commercialisation of discoveries.
Applications to BMTH3.0 will go through a two-stage process. Stage one’s eligible non-confidential EOIs will be reviewed by an independent selection panel of research, industry and investment experts.
Round One of the BMTH programme saw $10 million successfully deployed to 11 projects in 3D anatomical printing and precision medicine. Applications for Round Two targeted unmet clinical needs in four therapeutic areas: cardiovascular, orthopaedics, ophthalmology and emergency medicine and trauma. It closed in July this year and applications have been shortlisted, with funding announcements to be made before the end of the year.
EOIs close 16 December 2019.
Further details can be found here.